Shanghai Zhangjiang Biobank Established!
Shanghai Zhangjiang Biobank Established!
Precise biological molecular medical big data could only be obtained from precise biological samples and then be transformed into medical achievement through industrialized R&D, such as big sample validation and clinical trials, and eventually realize “precision medicine”.
With an investment of RMB100 million from Zhangjiang Management Committee, Shanghai Zhangjiang Biobank was officially established on July 30, 2016, with a capacity of storing 1,000 biological samples. It will strive to evolve into Shanghai National Biobank!
We learned this from the “2016 Shanghai ‘Chip’ Medicine Summit - Study on Transformation from “Sample” to “Product” and precision medicine”, a forum to celebrate the 15th anniversary of Shanghai Biochip Ltd. Co. (Biochip Shanghai National Engineering Research Center).
This forum was attended by many academicians and experts, including academician Chen Zhu, Vice Chairman of Standing Committee of NPC and Chief Scientist of National Engineering Research Center, academician Shen Xiaoming, Member of Standing Committee of Municipal Party Committee, academician Fan Daiming, Vice President of Chinese Academy of Engineering and academician Cao Xuetao, Chinese Academy of Medical Science as well as dozens of academicians and experts.
How important is biobank?
Biological sample is the key source for the fundamental and clinical study of epidemiology and life science, and the core session for molecule medicine to conduct big sample validation and quickly realize bio-pharma transformation study and precision medicine.
Biobank mainly collect, preserve various human biological samples for multiple researches (exclude organ transplant), including tissue, cell, various body fluids, as well as various information on clinical materials and visits related to these biological samples.
In last decade, developed countries in Europe and the U.S. gradually established their national biobanks. In 2009, Times magazine ranked biobank in top 10 plans that would change the future world.
▪ NCI in the U.S. took advantage of governmental fund in 2009 by investing USD3 billion at one time and its first project was national biobank.
▪ UK has a biobank with a capacity of storing 500,000 samples.
▪ Canada raised CAD3 billion to establish national tumor resource online system.
▪ Japan raised JPY5 billion to establish a resource base for institue of health science.
▪ January, 2015, Obama announced to launch “precision medicine” plan and sample resource base was also a key investment. America also has company specializes in providing third party biological sample storage and management, and it is world’s third largest biological sample storage and management center.
Biobank starts late in China and faces many problems and bottlenecks: such as problems of standard, quality and talent; there are many “rubbish bank” (dirt)
Hospitals, departments, experts, pharmaceutical enterprises and individuals expect a unified national standard and to invest to build a safe and reliable national resource center, third party storage site and platform for information sharing and exchange . Therefore, the establishment of national biobank, third party biological sample storage center and virtual sample storage platform attract attention of the industry.
Why settled in Zhangjiang?
China has a large population with extremely ample genetic resources in disease types; China is also a multi-nationality country, which has diversity and local features in major diseases, for example, Lin County in He’nan Province has a high incidence of esophageal cancer and Qidong City in Jiangsu Province has a high incidence of liver cancer. Therefore, there is a solid foundation for building a standard and precious biobank. In short, China is an ideal place for building biobank.
First settlement in Zhangjiang attributes to previous solid foundation!
Founded in 2001, Shanghai Biochip Ltd. Co. (Biochip Shanghai National Engineering Research Center ) (hereinafter referred to as “center”) is located in Zhangjiang Libing Road. Approved by National Development and Reform Commission, it is one of the centers in China’s life science field with the largest investment.
During its 15 years’ development, the center took the lead to establish a standard biobank with 400,000 samples and the first intensified biobank, that is, smart, automobile and information-based “biobank”. It is also the first biobank model in China.
Gao Hengjun, Director of Biochip Shanghai National Engineering Research Center revealed that they hope the center could move forward to become Shanghai National BioBank, with a capacity of storing 30 million to 50 million pieces of samples.
“China BioBank Alliance”
Led by the center, “China BioBank Alliance” was officially established during this forum with the support of over 50 famous AAA-level hospitals. This alliance was initiated by Yang Shengli, academician of Chinese Academy of Engineering and Professor Gao Hengjun from Shanghai National Engineering Research Center , and many hospitals from Beijing, Shanghai, Tianjing, Guangdong, Jiangsu, Zhengjiang and so on joined the alliance as founding members.
It is the first industrial and professional alliance initiated by social medical institute and approved by authorities. Its aim is to drive and promote the standardization in China’s biobank, build connections in biological sample industry chain, lead new model of biobank and provide information to government and contribute to the development of precision medicine and human health.
“Dozens of academicians gathered in Zhangjiang”
To further explore major issues such as R&D, clinical transformation and precision medicine practice in molecule medicine area, and make greater contributions to China’s innovation in biology technology and industrial development, Shanghai Biochip Co., Ltd. organized this summit and invited dozens of top scientists in biological medicine area and clinical experts, including dozens of academicians and experts to deliver keynote speeches.
Academicians like Chen Zhu, Fan Daiming, Cao Xuetao and Cheng Jing gave speeches “Human Genome: Change of Medicine”, “Integration of Medicine”, “Status quo and Future of Immune Cell Therapy”, “Biochip Technology and Industry: Where is the Road” respectively, participants thus had the opportunity to learn the latest views and progress in this area. Academician Fan Daiming won applause with his humor and vivid descriptions.
Academician Fan Daiming, Vice President of Chinese Academy of Engineering
The inauguration of China BioBank Alliance and Shanghai Zhangjiang BioBank is a sign of another great step towards precision medicine. Though the arrival of China’s biology big data era is unsure, it will definitely serve as a driver for the building of our biobank.